Table 1.
Study entry demographics for the five cohorts.
| START | FIRST | ESPRIT | SMART | STALWART | |
| Participants (n = ) | 2546 | 544 | 2891 | 2283 | 244 |
| Age (years): median (IQR) | 36 (29, 45) | 38 (32, 44) | 40 (34, 46) | 44 (38, 50) | 36 (30, 44) |
| Female (%) | 20.1 | 20.2 | 18 | 26 | 18 |
| Race | |||||
| Asian (%) | 1 | <1 | 12 | 1 | 27 |
| Black (%) | 23 | 57 | 9 | 38 | 6 |
| White/other (%) | 76 | 43 | 79 | 60 | 68 |
| CD4+ cell count (cells/μl): median (IQR) | 651 (585, 759) | 181 (43, 345) | 451 (368, 582) | 572 (455, 773) | 419 (358, 516) |
| HIV RNA level (log10 copies/ml): median (IQR) | 4.17 (3.54, 4.66) | 5.09 (4.53, 5.54) | 1.70 (1.70, 2.60) | 2.60 (1.70, 3.45) | 4.38 (3.86, 4.79) |
| CD8+ T-cell count (cells/μl): median (IQR) | 1062 (790, 1431) | n/a | n/a | n/a | n/a |
| Nadir CD4+ T-cell count (cells/μl): median (IQR) | 545 (473, 642) | n/a | n/a | n/a | n/a |
| CD4/CD8 ratio: median (IQR) | 0.62 (0.46, 0.84) | n/a | n/a | n/a | n/a |
| IL-6 (pg/ml): median (IQR) | 1.47 (1.02, 2.21) | n/a | 1.90 (1.30, 2.80) | 1.91 (1.19, 3.23) | n/a |
| CRP (μg/ml): median (IQR) | 1.82 (0.77, 4.15) | n/a | 1.49 (0.69, 3.21) | 1.79 (0.76, 4.51) | n/a |
| D-dimer (μg/ml): median (IQR) | 0.31 (0.22, 0.47) | n/a | 0.26 (0.18, 0.37) | 0.22 (0.13, 0.40) | n/a |
| On ART at study entry (%) | 0 | 0 | 100 | 79.5 | 0 |
| ART-naive (%) | 100 | 100 | 0 | 6.0 | 78 |
| Geographical region a | |||||
| U.S. (%) | 18 | 100 | 25 | 80.4 | 10 |
| Europe/Australia/Israel (%) | 49 | 0 | 49 | 11.2 | 34 |
| South America/Mexico (%) | 20 | 0 | 14 | 5.5 | 30 |
| Asia (%) | 0 | 0 | 11 | 0.4 | 25 |
| Africa (%) | 13 | 0 | 1 | 2.5 | <1% |
CRP, C-reactive protein; IL-6, interleukin 6; IQR, interquartile range.
a
Country/region of residence.